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Previous epidemiologic studies suggest that antihypertensive drugs may be protective against cognitive decline. To determine if
subjects enrolled in the University of Kentucky longitudinal aging study who used antihypertensive drugs showed diminished
progression to dementia, we used a 3-parameter logistic regression model to compare the rate of progression to dementia for
subjects who used any of the five common categories of antihypertensive drugs to those with similar demographic characteristics
but who did not use antihypertensives. Regression modeling showed that subjects who used calcium channel blockers (CCBs) but
not the other classes of antihypertensives showed a significant decrease in the rate of progression to dementia. Significantly, use of
CCBs ameliorated the negative effects of the presence of APOE-4 alleles on cognitive decline. To determine if CCBs couldminimize
amyloid beta peptide (A𝛽1–42) production, H4 neuroglioma cultures transfected to overexpress APPwere treated with various CCBs
and A𝛽1–42 levels and levels of proteins involved in A𝛽 production were quantified. Results show that treatment with nifedipine led
to a significant decrease in levels of A𝛽1–42, with no significant decrease in cell viability. Collectively, these data suggest that use of
CCBs significantly diminishes the rate of progression to dementia and may minimize formation of A𝛽1–42.
1. Introduction
Alzheimer’s disease (AD) is the 6th leading cause of death
in the United States and today affects 5.2 million Americans
aged 65 and more [1]. Without preventive strategies or devel-
opment of an efficacious treatment, there may be 16 million
Americans with AD by the year 2050 [1].
Pathologically, AD is characterized by an abundance of
neurofibrillary tangles (NFT), senile plaques (SP), neuropil
thread formation, and A𝛽 deposition; neuron and synapse
loss; and proliferation of reactive astrocytes, particularly in
the hippocampus, amygdala, entorhinal cortex, and neocor-
tex.NFT are composed of intracellular deposits of paired heli-
cal filaments composed of hyperphosphorylated tau. Senile
plaques are present as diffuse plaques composed of amor-
phous extracellular deposits of amyloid beta (A𝛽) that lack
neurites and neuritic plaques (NP) composed of extracellular
deposits of insoluble A𝛽 surrounded by dystrophic neurites,
reactive astrocytes, and activated microglia. In addition to
insoluble A𝛽 present in SP, soluble A𝛽 oligomers are present
in theADbrain andmay represent themain toxic formofA𝛽,
thus implicating them in the disease process [2–4].
Currently, two classes of medications are FDA approved
for use by AD patients including cholinesterase inhibitors
(Aricept) and an N-methyl-D-aspartate (NMDA) antagonist
(Memantine). Although these therapeutics show clinical
benefit in some patients, many do not respond. Additionally,
these drugs do not significantly modify disease progression
and perhaps more importantly are not approved for patients
at earlier stages of the disease (mild cognitive impairment;
MCI). For these reasons there is a critical need to identify
additional therapeutics that can be initiated early in disease
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progression to alter the pathogenesis of the disease. To date,
most experimental therapeutics have focused on modulation
of the major pathologic features of the AD brain by designing
drugs that decrease formation of the 42-amino acid amyloid
beta peptide (A𝛽
1–42) or modify its capacity for formation of
neurotoxic oligomers or the modulation of tau hyperphos-
phorylation and NFT formation through manipulation of
kinases responsible for tau phosphorylation.
Although several therapeutic compounds have been
developed and tested for use in AD, none to date have proven
useful in the modulation of the pathogenesis of AD and
the cognitive decline associated with disease progression.
In an attempt to identify drugs commonly used by elderly
patients that may diminish cognitive decline, multiple ret-
rospective epidemiologic studies have been carried out. One
class of potentially beneficial drugs identified is antihyper-
tensives (AHTs). Recent prospective cohort studies suggest
that hypertension in midlife is associated with increased
risk of dementia in later life [5–12] and increased risk
of hippocampal atrophy [13]. Multiple studies suggest that
various AHTs may be effective in slowing cognitive decline
although it remains unclear if protective effects observed are
due to cardiovascular protection. To determine if volunteers
enrolled in the University of Kentucky Alzheimer’s Disease
Center (UK-ADC) Biologically Resilient Adults in Neuro-
logical Studies (BRAiNS) cohort prescribed AHTs showed
slower progression to dementia compared to subjects not
taking AHTs, we used a three-parameter logistic model to
analyze cognitive and clinical data maintained by the UK-
ADC Biostatistics Core. In addition, we tested the effect of
various AHTs on formation of amyloid beta peptide (A𝛽
1–42)
in cell culture.
2. Materials and Methods
2.1. Case-Control Study. Subjects of this study were drawn
from volunteers in the BRAiNS cohort at the UK-ADC,
a longitudinal cohort of approximately 1,100 individuals
established in 1989 with ongoing recruitment [14] as shown
in Figure 1. The cohort comprises a convenience sample
of older adults (age ≥ 60 years) from central Kentucky.
Exclusion criteria for the BRAiNS cohort include prevalent
neurological, psychiatric, and disabling medical disorders, as
well as prevalent dementing illness (see [14] for a detailed
listing and explanation of recruitment and procedures). Par-
ticipants undergo annual cognitive and clinical assessments
and donate their brains upon death. All volunteers were
cognitively normal at study entry, and all research activities
were approved by the University of Kentucky Institutional
Review Board. Each participant provided written informed
consent.
Initial inclusion criteria for the current study included at
least two clinical assessments with an assessment of at least
mild dementia during follow-up (MMSE ≤ 26) or clinical
diagnosis of dementia and known APOE genotype (𝑛 =
274). Eligible subjects were identified who reported use of
AHT medications from each of the 5 commonly prescribed
categories (angiotensin converting enzyme (ACE) inhibitors,
1,126 BRAiNS 
volunteers enrolled 
168 enrolled after 
July 1, 2009
83 were missing APOE
98 had only one MMSE 
assessment
503 had no dementia
274 were initially eligible for 
current study
167 used AHT 107 never used AHT 
82 were AHT 
monotherapy users
79 were matched controls 
67 were ACE-inhibitor, 
beta-blocker, or 
calcium channel 
blocker users 
65 were matched controls 
Figure 1: Flow chart demonstrating subject stratification leading to
subjects included for analysis.
angiotensin II receptor blockers, beta-blockers, calcium
channel blockers (CCBs), or diuretics; Table 1) and were
designated as AHT-positive subjects (𝑁 for each category
shown in Table 1). Participants who reported use of multiple
AHT drugs were excluded.These AHT-positive subjects were
matched as closely as possible to subjects who never reported
taking AHTs (AHT-negative) by age of entrance into the
study group, by gender, and as closely as possible by the
number ofMMSE assessments (taken before and after the age
medications began). Subject demographic data are shown in
Table 2. Cognitive and clinical data maintained by the UK-
ADCBiostatistics Corewere analyzed to determine if subjects
using the 5 classes of commonly prescribed AHTs showed
diminished cognitive decline measured by MMSE scores
compared to subjects without AHT therapy. Because medical
history data were not routinely collected until 2001, presence
of hypertension could not be included in the analysis. Studies
described in the paper were carried out in accordance with
The Code of Ethics of the World Medical Association (Dec-
laration of Helsinki) for experiments involving humans and
were approved by the University of Kentucky Institutional
Review Board.
2.2. H4 Survival and A𝛽 Measurement. To determine if
CCBs lead to altered A𝛽 processing in vitro, H4 human
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Table 1: Commonly prescribed antihypertensive drugs.
Antihypertensive category Drugs
Angiotensin converting
enzyme (ACE) inhibitors
Benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec), fosinopril (Monopril), lisinopril
(Prinivil, Zestril), moexipril (Univasc), quinapril (Accupril), ramipril (Altace), and trandolapril
(Mavik)
Angiotensin II receptor
blockers
Candesartan (Atacand), irbesartan (Avapro), losartan (Cozaar), telmisartan (Micardis), and
valsartan (Diovan)
Beta blockers
Acebutolol (Sectral), atenolol (Tenormin), betaxolol (Kerlone), bisoprolol (Zebeta), carteolol
(Cartrol), carvedilol (Coreg), labetalol (Normodyne, Trandate), metoprolol (Lopressor, Toprol),
nadolol (Corgard), penbutolol (Levatol), propranolol (Inderal), and timolol (Blocadren)
Calcium channel blockers
Amlodipine (Norvasc), clevidipine (Cleviprex), dilitiazem (Cardizem), felodipine (Plendil),
isradipine (Dynacirc), nifedipine (Adalat, Procardia), nicardipine (Cardene), nimodipine
(Nimotop), and nisoldipine (Sular)
Diuretics Acetazolamide (Diamox), chlorthalidone (Thalitone), hydrochlorothiazide (HydroDiuril),indapamide (Lozol), and metolazone (Zaroxolyn, Mykrox)
Table 2: Subject demographic data for subjects involved in the logistic modeling study. There were insufficient numbers of subjects taking
diuretics or angiotensin II receptor blockers to allow meaningful comparisons.
CCBs ACE Beta blockers
Users Matchednonusers All Users
Matched
nonusers All Users
Matched
nonusers All
𝑁 32 31 63 13 13 26 22 21 43
Initial age
(mean ± SEM y) 75.4 ± 1.2 75.4 ± 1.2 75.4 ± 0.8 77.5 ± 1.6 76.9 ± 1.7 77.2 ± 1.1 75.5 ± 1.7 76.1 ± 1.7 75.8 ± 1.2
Age/pseudoage at
drug initiation
(mean ± SEM y)
79.2 ± 1.3 78.8 ± 1.3 79.0 ± 0.9 81.1 ± 2.1 81.1 ± 1.6 81.1 ± 1.6 79.4 ± 1.8 79.4 ± 1.8 79.2 ± 1.2
% women 73.5 75.0 74.2 61.5 61.5 61.5 52.4 54.2 52.4
Baseline
comorbidities
(𝑛 [%])
Heart attack 3 (9.4) 1 (3.2) 4 (6.4) 1 (7.7) 0 (0.0) 1 (4.0) 3 (13.6) 0 (0.0) 3 (7.0)
Hypertension 18 (56.3) 6 (20.0) 24 (38.71) 3 (23.1) 0 (0.0) 3 (12.0) 6 (27.3) 0 (0.0) 6 (14.0)
Diabetes 3 (9.4) 1 (3.2) 4 (6.4) 2 (15.4) 1 (8.3) 3 (12.0) 1 (4.5) 2 (9.5) 3 (7.0)
High
cholesterol 5 (15.6) 3 (10.3) 8 (13.11) 1 (7.7) 0 (0.0) 1 (4.0) 4 (18.2) 1 (4.8) 5 (11.6)
neuroglioma cell lines transfected to overexpress the amy-
loid precursor protein (APP) (H4-APP cells) [15, 16] were
maintained in Opti-MEM (Invitrogen) with 10% fetal bovine
serum (FBS) and hygromycin B (0.2mg/mL) and were split
1 : 2 every two days. For treatment, cells were plated at 2.5
× 105 cells/well in 6-well plates and allowed to grow for 24
hours. Cultures were switched toOpti-MEMand treatedwith
CCBs or vehicle (DMSO) for 16 hours. Following treatment,
media were collected from each well, mixed with 5 𝜇L 50mM
EDTA, and flash-frozen until used for A𝛽 quantification. An
equivalent volume of Opti-MEM was added to each well and
cell viability assessed by adding 3-[4,5-dimethylthiazol-2yl]-
2,5-diphenyl tetrazolium bromide (MTT) (500 𝜇g/mL final
concentration) as a measure of cell viability.
2.3. A𝛽 ELISA. Levels of A𝛽
1–42 secreted into the medium
were quantified using standard sandwich ELISAs (Invitro-
gen) as per manufacturer’s instructions. Data are reported as
the mean ± SEM % control (vehicle) A𝛽
1–42.
2.4. Western Blot Analysis. For quantification of proteins
involved in A𝛽 processing H4 cells were plated at 2.5 ×
105 cells/well in 6-well plates and allowed to grow for 24
hours. Based on results of survival studies, cells were treated
with 1 𝜇M nifedipine or vehicle for 16 hours. Following
treatment cells were rinsed 3 times in PBS and cells from a
single plate collected to make a single sample. Experiments
were carried out using 6 to 9 samples (plates) per treat-
ment. Cell pellets were homogenized in HEPES containing
137mM NaCl, 4.6mM KCl, 0.6mM MgSO
4
, 0.7 𝜇g/mL
pepstatin A, 0.5𝜇g/mL leupeptin, 0.5 𝜇g/mL aprotinin, and
40 𝜇g/mL phenyl methyl sulphonyl fluoride, using an insulin
syringe with a 26-gauge needle. Samples were centrifuged
at 16,000×g for 10 minutes and the supernatant was used
for western blot analyses. Protein samples (20𝜇g) were
boiled in 4x SDS loading buffer for 5min and separated
by electrophoresis on 4–15% gradient sodium dodecyl sul-
fate polyacrylamide gels, transferred to nitrocellulose mem-
branes, and probed using antibodies against BACE-1 (R&D
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Systems; 1 : 1500 dilution; MW identified = 56 kDa), PS-1
(Cell Signaling; 1 : 750 dilution; MW = 55 kDa (full length)),
NCT (Cell Signaling; 1 : 1500 dilution; MW = 120/110 kDa),
cleavedNotch-1 (Novus; 1 : 1500;MW=80 kDa), andADAM-
10 (presumed 𝛼-secretase; Santa Cruz; 1 : 1500 dilution; MW
(active) = 60 kDa). Band intensities were quantified using a
Li-Cor system and results normalized to levels of GAPDH on
each gel. Results are expressed as mean ± SEM % vehicle.
2.5. Statistical Analysis. Since MMSE scores are known to
decline with age and are bounded between 0 (floor) and 30
(ceiling), the scores were regressed on the age at which they
were obtained using a three-parameter logistic regression
model described below. The model has a random effect to
account for the correlation among responses obtained from
the same subject over time. All computationswere done using
the NLMIXED procedure in PC-SAS version 9.2.
The three-parameter logisticmodel used in the regression
analysis was defined as
𝑌
𝑖𝑡
=
𝑎
1 + exp {𝑏 (𝑡 − 𝑐)}
, (1)
where 𝑌
𝑖𝑡
represents the MMSE score for the 𝑖th subject at
age 𝑡. The parameter 𝑎 is the asymptote for that subject,
which varies by subject, the parameter 𝑏 is a scaling effect
representing 75% of the asymptote, and the parameter 𝑐 is the
midpoint of the curve or 50% of the asymptote. We assume
that only the parameter 𝑐 depends on the fixed effects while
the parameter 𝑎 depends only on the random effect and
𝑏 is a scaling parameter. The fixed effects, or covariates of
interest, are educational level, initial age, APOE-4 status, and
AHT-positive/AHT-negative status. Since education did not
influence the midpoint parameter (𝑃 > 0.10), it was dropped
from the final model. The random effects are assumed to
follow independent normal distribution (across subjects)
with mean 30 (the ceiling) and unknown variance and are
assumed to be the asymptote 𝑎 in the model. The purpose
of the modeling was to determine how each parameter
depended on these covariates after accounting for the two
sources of variability defined by the random effect: between-
and within-subject variability.
Statistical analyses for cell culture studies were carried out
using analysis of variance (ANOVA) with Dunnett’s post hoc
test for individual differences and the commercially available
ABSTAT (AndersonBell, Arvada, CO, USA) software.
3. Results
Subjects were selected from the UK-ADC database who
reported taking any of the 5 classes of AHTs following the
flow diagram shown in Figure 1 and shown in Table 1. The
database of MMSE scores consisted of 603 observations
taken on 63 subjects (31 AHT-negative and 32 AHT-positive
subjects) (one AHT-negative and two AHT-positive subjects
had missing data on APOE-4 status and were omitted from
the analysis) for subjects taking CCBs; 26 subjects (13 AHT-
negative and 13 AHT-positive subjects; 200 observations) for
subjects taking ACE inhibitors; and 43 subjects (21 AHT-
negative and 22 AHT-positive subjects; 238 observations) for
Table 3: Statistical parameters based on fit of the model to the data.
Parameter Estimate Standarderror DF 𝑡 value Pr > |𝑡|
Intercept 𝑏 0.1253 0.01288 62 9.72 <0.0001
Intercept c 17.0396 8.0292 62 2.12 0.0378
Case versus
control 3.6125 1.3639 62 2.65 0.0102
APOE-4 −3.8579 1.4064 62 −2.74 0.0079
Initial age 1.0278 0.1039 62 9.89 <0.0001
Between var. 15.1200 0.9212 62 16.41 <0.0001
Within var. 15.3807 3.3457 62 4.60 <0.0001
subjects on beta-blockers. Identification of subjects who took
only diuretics (𝑁 = 9) or angiotensin II receptor blockers
(𝑁 = 6) showed too few subjects to allow stratification by
APOE-4 status, and they were not included in the analysis.
After carrying out regression analysis for groups on each of
the three drugs the resulting best fit of the data showed that
the parameter 𝑏 did not depend on any of the fixed effects
while the parameter 𝑐 depended on three covariates: initial
age (𝑃 < 0.0001), APOE-4 status (𝑃 = 0.008), andAHT status
(𝑃 = 0.01) for subjects taking CCBs. Since the parameter 𝑐 is
a linear combination of these three covariates, details on the
beta estimate and standard errors can be found in Table 3.
Subjects taking the other AHTs did not show significant
effects on progression to severe global cognitive impairment.
To illustrate the fit of the model to the data, Figure 2
shows the trajectory of the fittedmodel versus age for subjects
enrolled in the cohort at initial age 75. Based on Table 3
this trajectory varies by AHT status and APOE-4 status.
The effect of each variable is about the same (a shift of 3.6
years for AHT-positive subjects compared to AHT-negative
subjects and a shift of 3.8 years for no APOE-4 versus APOE-
4 subjects). Specifically, the parameter 𝑐 accounts for a shift
at the midscore (MMSE score of 15) with a shift of roughly
3.7 years for each of these variables at that score. In other
words, it takes an AHT-positive subject (those on CCBs) 3.6
years longer to attain the MMSE score 15 than those not
on medications. As expected, the analyses showed that the
presence of APOE-4 alleles led to an accelerated trajectory
of progression to severe global cognitive impairment. In
contrast, APOE-4 positive subjects who were prescribed
CCBs showed a significant protective effect and a trajectory
to dementia equivalent to that of subjects without APOE-4
alleles or CCB use. Additionally, subjects without APOE-4
alleles who reported use of CCBs showed significantly slower
progression to severe global cognitive impairment (∼4 years).
3.1. Cell Culture Studies. Because the regression model sug-
gested that use of CCBs is associated with slowed progression
to dementia we wanted to determine if CCB treatment sig-
nificantly impacts pathogenic processes associated with AD.
To determine if CCBs diminish A𝛽
1–42 formation we treated
H4neuroglioma cultures overexpressingAPPwith increasing
concentrations of the 8 most commonly prescribed CCBs
(amlodipine, dilitiazem, felodipine, isradipine, nicardipine,
Oxidative Medicine and Cellular Longevity 5
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Figure 2: Plot of the estimated rate of decline in MMSE scores
across the age span: top curve (light blue) shows patients who were
APOEnegativewho usedCCBs; the 2nd curve (black) showsAPOE-
4 negative patients without CCB use; the third curve (red) which lies
just below the 2nd is for APOE-4 positive subjects who used CCBs;
and the bottom curve (dark blue) is APOE-4 positive subjects who
did not use CCBs.
nimodipine, nifedipine, or nisoldipine) andmeasured A𝛽
1–42
secretion into culture medium. Cultures were treated with
each drug for 16 hours and cell viability was assessed using
the reduction of MTT. Figure 3 shows that 1𝜇M amlodipine,
dilitiazem, felodipine, isradipine, nicardipine, and nifedipine
led to minimal cell death whereas higher concentrations of
nisoldipine (10 𝜇M)were well tolerated by the cultures. Using
these optimized concentrations for further studies, we plated
H4 cultures in 6-well plates at a density of 2.5 × 105 cells/well
and after 24 hours of equilibration exposed the cells to each
agent (𝑁 = 9 to 18 over three experiments) for 16 h. Following
treatment, medium was collected and mixed with 5𝜇L 1mM
EDTA to inhibit metalloprotease activity and A𝛽
1–42 levels
secreted into culturemediumquantified using standard sand-
wich ELISAs (Invitrogen) as per manufacturer’s instructions.
Figure 2 shows that of the 8 CCBs tested 1 𝜇M nifedipine,
1 𝜇M nimodipine, and 10 𝜇M nisoldipine led to significantly
lower A𝛽
1–42 generation with nifedipine showing the most
pronounced change. It is interesting to note that nifedipine
and nisoldipine are unique among CCBs in that both contain
an ortho-nitro groupwhereas the other drugs contain ameta-
nitro group.
Because nifedipine treatment led to themost pronounced
decrease in A𝛽
1–42 production with minimal cell toxicity, we
chose to use it for further study of the potential effects of
representative CCBs on proteins involved in A𝛽 processing.
For these studies, H4 cells were plated at a density of 2.5
× 105 cells/well in 6-well plates and were exposed to 1𝜇M
nifedipine for 16 hours. Following exposure, the cells were
rinsed in PBS and cells from 6 wells were combined to
generate a single sample for protein analyses (𝑁 = 3 to
6 samples (plates) per treatment). Cells were homogenized
using a micro-Dounce homogenizer and protein content was
measured using the Pierce BCA method as per manufac-
turer’s instructions. Protein samples (20 𝜇g) were subjected
to SDS/PAGE using 5 to 20% linear gradient gels and trans-
ferred to nitrocellulose and probed with antibodies against
MTT reduction
Vehicle
1𝜇M nifedipine
1𝜇M amlodipine
1𝜇M dilitiazem
1𝜇M felodipine
1𝜇M isradipine
1𝜇M nicardipine
1𝜇M nimodipine
10𝜇M nisoldipine
M
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n
±
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M
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ic
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∗
P < 0.05
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P < 0.10
A𝛽
1–42
∗
∗∗
∗
∗∗
∗∗
Survival
Figure 3: Mean ± SEM H4 survival and A𝛽
1–42 production after
treatment with commonly prescribed CCBs. ∗𝑃 < 0.05.
BACE-1 (R&D Systems; 1 : 1550 dilution; MW identified =
56 kDa), PS-1 (Cell Signaling; 1 : 750 dilution; MW = 55 kDa
(full length)), NCT (Cell Signaling; 1 : 1500 dilution; MW =
120/110 kDa), cleavedNotch-1 (Novus; 1 : 1500 dilution;MW=
80 kDa), and ADAM-10 (presumed 𝛼-secretase; Santa Cruz;
1 : 1500 dilution; MW (active) = 60 kDa). Figure 4(a) shows
representative western blots for each protein. Figure 4(b)
shows that treatment with nifedipine led to a statistically
significant decrease of PS-1, and a significant increase in
ADAM-10 compared to cultures treated with vehicle alone
(DMSO) suggesting that the decrease in A𝛽 observed may be
due to diminished 𝛽- and 𝛾-secretase activity and increased
𝛼-secretase activity.
4. Discussion
Although several therapeutic compounds have been devel-
oped and tested for use inAD, none to date have provenuseful
in the modulation of the pathogenesis of AD and the cogni-
tive decline associatedwith disease progression. In an attempt
to identify drugs commonly used by elderly patients that
may diminish cognitive decline, multiple retrospective epi-
demiologic studies have been carried out. One class of drugs
identified is antihypertensives (AHTs). Several prospective
cohort studies of 3290 subjects in CacheCountyUtah showed
a lower incidence of AD in subjects taking AHTs at base-
line (particularly potassium sparring diuretics) compared to
those who did not [17]. More recently, a longitudinal study
of 1810 patients aged 75 years and more in the Kungsholmen
district of Stockholm, Sweden, showed that patients taking
diuretics had a lower rate of dementia, whereas other AHTs
including 𝛽-blockers and calcium channel blockers (CCBs)
did not [18]. More recent randomized placebo controlled
studies show that subjects over 60 years of age from 19
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Figure 4: (a) Representative western blots for proteins involved in A𝛽 processing in H4 neuroglioma cells treated with nifedipine. (b) Levels
of proteins involved in A𝛽 processing following treatment with nifedipine. Results are reported as mean ± SEM percent vehicle treated cells.
∗
𝑃 < 0.05.
countries in Europewith no history of dementiawho received
active treatment with the CCB nitrendipine followed by
enalapril or hydrochlorothiazide (𝑛 = 1238) had an 80%
decreased risk of dementia or AD compared to placebo con-
trol (𝑛 = 1180) [19–22]. The Perindopril Protection Against
Recurrent Stroke Study (PROGRESS), which included 6105
patients with a history of stroke or ischemia from 10 countries
receiving perindopril and indapamide, showed a significant
reduction in cognitive decline compared to those receiving
placebo controls [23]. In contrast, the Study onCognition and
Progression in the Elderly (SCOPE) [24–27] and the Systolic
Hypertension in the Elderly Program (SHEP) showed no sig-
nificant differences between subjects provided active agents
(candesartan/hydrochlorothiazide (SCOPE); chlorthalidone,
atenolol, or reserpine (SHEP)) compared to placebo controls,
although further analyses showed that most of the placebo
controls were concurrently taking AHTs [28–31]. A more
recent population study of 54 patients taking CCBs, 59
patients on angiotensin converting enzyme (ACE) inhibitors,
81 on 𝛽-blockers, and 16 on diuretics followed from ages
85 to 90 showed that patients on CCBs but not other
AHTs had a slower decline in MMSE score (0.4 MMSE
units/year) compared to control subjects not on AHTs [32].
Themost recent analysis of data from theCacheCounty Study
suggests that thiazide and potasssium sparing diuretics were
associated with decreased risk of AD [33]. More recently,
meta-analysis of data from 10 studies of the relationship
between CCBs and later cognitive decline showed no clear
evidence that CCB use increased or decreased the risk of
cognitive decline or dementia in the very elderly [34].
In contrast to previous studies that evaluated the risk of
AD and use of AHTs (including those in the recent meta-
analyses) our current study examined the potential effects
of AHTs on progression to dementia in a well-characterized
group of subjects rather than assessment of risk. Our results
demonstrate that use of CCBs but not other groups of AHTs
significantly decreases the rate of progression of subjects
to dementia compared to subjects who took no AHTs.
In addition, and perhaps most importantly, use of CCBs
mitigated the accelerated decline to dementia associated with
the presence of the APOE-4 allele. Although several studies
(reviewed in [33]) have suggested that diuretics, particularly
potassium sparring diuretics,minimize the risk of developing
AD in prospective studies, our study cohort had too few
subjects who took only diuretics or angiotensin II receptor
blockers for inclusion in the analyses.
Although AHTs appear to significantly alter the risk of
development of AD, the exact mechanism remains unclear
and is possibly a combination of cardiovascular effects cou-
pled with potential effects on the pathogenic mechanisms of
AD.
To examine the potential effects of CCBs on amyloid
processing we treated H4 cultures with multiple CCBs
and assessed cell survival and the effects of each drug
on A𝛽
1–42 production. Our data show that of the CCBs
tested nifedipine provided the most pronounced reduction
(∼40%) in A𝛽 production coupled with the least toxicity.
To determine if nifedipine treatment significantly altered
proteins associated with A𝛽 production we examined levels
of proteins involved in A𝛽 processing. Our data show that
nifedipine treatment significantly decreased levels of key
components of the gamma secretase complex (PS-1, NCT). In
addition, nifedipine significantly increased levels of ADAM-
10, a presumed alpha secretase.These data are in contrast with
those of Zhao et al. [35] who showed no A𝛽
1–42 lowering
effects of common antihypertensive drugs although they
found significant effects of furosemide (diuretic), nitrendip-
ine (CCB), candesartan (angiotensin II receptor antagonist),
and diazoxide (vasodilator) against A𝛽
1–42 oligomerization.
Although cell culture data are often difficult to extrapolate
to human subjects in the clinic, our data suggest that a possi-
ble additional mechanism of action of nifedipine is through
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modulation of A𝛽 production. Clearly, further studies are
needed to determine if CCB use correlates with decreased
amyloid plaque deposition in AD subjects.
Modulation of A𝛽 has been the focus of considerable
study as a potential therapeutic target in recent years. A𝛽
is formed by sequential cleavage of the amyloid precursor
protein (APP) by the 𝛽-site APP cleaving enzyme (BACE), an
aspartyl protease, to form theN-terminal of A𝛽.The resulting
C-terminal fragment of APP is cleaved at multiple sites by
the 𝛾-secretase complex that consists of presenilin-1 (PS-1),
nicastrin (NCT), presenilin enhancer-2 (Pen-2), and APH-
1 [36] to form A𝛽 peptides ranging from 37 (A𝛽
37
) to 43
(A𝛽
43
) residues. In contrast, normal processing of APP by 𝛼-
secretase (presumed ADAM-10) leads to cleavage of APP in
the middle of the A𝛽 sequence and the formation of secreted
APP (sAPP𝛼), a neurotrophicmolecule. Increased processing
of APP by BACE and 𝛾-secretase leads to production of A𝛽
fragments that form neurotoxic oligomers and fibrils before
final aggregation as SP [37, 38]. Multiple studies demon-
strate that oligomeric A𝛽 inhibits long term potentiation
and memory when injected into rat brain [4, 39, 40] and
that oligomeric A𝛽 levels correlate with memory deficits in
transgenic mouse models that express mutant APP, PS1, or
their combination [41, 42]. Together these data have been
used to support studies of potential therapeutics that modify
A𝛽 formation including the development of BACE inhibitors
and inhibitors of the 𝛾-secretase complex.
Additional therapeutics aimed at minimizing A𝛽 pro-
cessing have focused on modulation of 𝛾-secretase. Inhibi-
tion of 𝛾-secretase diminishes A𝛽 formation, prevents A𝛽
aggregation, and reverses APP induced cognitive deficits in
transgenic models of A𝛽 deposition [43]. Unfortunately, 𝛾-
secretase functions in the cleavage of multiple transmem-
brane proteins in addition to APP, in particular the Notch
family of transmembrane receptors required for Notch sig-
naling [44]. Prolonged dosing of 𝛾-secretase inhibitors leads
to inhibition of Notch signaling and changes in the GI
tract, spleen, and thymus that likely limit the extent of A𝛽
inhibition [45–47]. Despite this potentially serious problem,
𝛾-secretase inhibitors including LY-50139 (Lilly [48, 49])
and MK0752 (Merck [50]) have been tested in humans.
Unfortunately, the clinical trials have not been successful
(reviewed [51]).
More recent pharmacologic approaches aimed at en-
hancedA𝛽 degradation havemainly focused on vaccinations.
Initial active vaccination trials using Elan’s AN1702 antibody
against A𝛽
42
aggregates led to meningeal encephalopathy
in 6% of the vaccinated patients and early termination
of the studies [52]. More recent studies have focused on
passive immunization with anti-A𝛽 antibodies. In trans-
genic models of A𝛽 deposition, passive immunization led
to decreased plaque burden [53] and reversal of cognitive
deficits [54]. Although passive immunization likely lim-
its encephalopathies associated with active immunization,
increased vascular amyloid has been observed in transgenic
models [55–57]. Bapineuzumab (Elan/Wyeth), a humanized
monoclonal antibody (reviewed [58]) that binds the N-
terminal region of A𝛽 and is therefore unlikely to recognize
monomeric or oligomeric A𝛽, and solanezumab (Eli Lilly),
a humanized A𝛽 antibody that binds monomeric but not
fibrillar A𝛽, recently failed to meet primary efficacy goals
in mild to moderate AD patients although pooled analyses
suggest that solanezumab may provide cognitive benefits
(reviewed [59]).
Overall, the current data suggest that use of calcium
channel blocker antihypertensives significantly slows the
rate of progression of subjects to dementia compared to
those subjects who do not use CCBs and that the potential
protective effects on cognitive decline might be mediated
through modulation of proteins involved in A𝛽 production.
The current data coupled with existing risk assessment
studies suggest that use of AHTs may significantly alter
AD risk/progression and that use of these drugs should be
considered in clinical trials of anti-AD therapeutics.
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